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ABSTRACT

MOUSE MODEL OF AORTIC ARTERIAL INJURY AND DENUDATION AND
POLYMERIC STENT DELIVERY IN MICE

Ashkon C. Nehzati

More than 385,000 people die from coronary heart disease (CHD) annually and treatment
costs $108.9 billion each year including the cost of health care services, medications, and
lost productivity. CHD decreases heart function by limiting oxygen and nutrient transport
carried through the coronary arteries. A complete block to the coronary arteries causes a
myocardial infarction in response to an elimination of blood supply to cardiomyocytes.
Partial occlusion results in insufficient blood supply to cardiomyocytes, producing
myocardial ischemia and angina, which are usually treated with intravascular stents
deployed percutaneously, before myocardial infarction occurs. Stents are the most
common ways to expand occluded vessels to treat CHD, with over 1 million stents placed
in coronary arteries each year. Unfortunately restenosis, the narrowing of vessels due to
endothelial damage and inflammation, is a common complication found after stenting
with rates for bare metal stents reported to be between 16% and 44% or about 160,000 to
440,000 patients. Even with the recent advancement in stent technology and the
introduction of drug eluting stents (DES), restenosis has continued to be a significant
problem associated with stenting. DES restenosis is estimated to occur in 200,000
patients in the United States. It has recently been found that DES may also put patients at
risk for late-stent thrombosis due to the delayed healing effects of the antiproliferative
coating. With medicine growing at a rapid pace, new stent designs are researched to
address new complications such as late-stent thrombosis. These newer designs need
newer animal models to better understand the response of the vascular wall to newer stent
technologies. The purpose of this study was to develop a mouse model of neointimal
hyperplasia in response to aortic endothelial denudation. This model would allow for
examination of the neointimal hyperplasia and endothelialization responses to next
generation intravascular technologies, such as polymeric stents.

Keywords: Stents, Neointimal Hyperplasia, Restenosis, Late-Stent Thrombosis, Coronary
Heart Disease, Ischemia, Bare Metal Stents, Drug Eluting Stents, Polymer Stents
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Chapter 1:

INTRODUCTION

CORONARY HEART DISEASE
Overview
Coronary heart disease (CHD) is an ischemic disease caused by the narrowing or
blockage of the coronary arteries due to atherosclerosis. The buildup of plaque on the
inner walls of the arteries physically restricts blood flow to the myocardium. Without a
sufficient supply of blood, the heart is unable to receive vital nutrients as well as a
consistent flow of oxygen, inducing myocardial ischemia, which presents as angina to the
patient. If the coronary artery becomes completely occluded, a myocardial infarct will
occur, and cardiomyocytes will necrose. Over time, CHD can cause enlargement of the
left ventricle, which can lead to heart failure and arrhythmias.
CHD is the most common type of heart disease and is the number one cause of
death for both men and women in the United States. More than 385,000 people die from
CHD annually and treatment costs $108.9 billion each year, including the cost of health
care services, medications, and lost productivity. Undiagnosed, CHD in sedentary
patients can lead to chest pain and myocardial infarction. Every year about 715,000
Americans have a myocardial infarction and in a 2005 survey, only 27% of the
individuals were aware of all major symptoms and to call emergency response during a
heart attack [1].
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Figure 1 – Atherosclerosis in Coronary Arteries. B, healthy coronary artery with normal blood flow.
C, diseased coronary artery with plaque buildup which leads to abnormal blood flow [2].

The major risk factors for CHD include family history of the disease, being of
male sex, African-American lineage, and advanced age. Other risk factors include
dyslipidemia, smoking, diabetes, obesity, hypertension, stress, poor diet, physical
inactivity, and excessive alcohol use.
Atherosclerosis, which is characterized by plaque formation in conduit vessels, is
the cause of CHD. Atherosclerosis pathology is hypothesized to be caused by endothelial
injury and inflammation which can often lead to the formation of atheromas. Risk factors
for atherogenesis can further aggravate the process leading to atherosclerotic plaque
accumulation. This plaque accumulation can restrict blood flow to the heart and
eventually result in infarcted cardiac tissue.
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Atherogenesis
Atherogenesis is the process that leads to the formation of atherosclerotic plaques.
Atherogenesis begins at bifurcations in response to turbulent shear stress by recruiting
inflammatory cells to the sub-endothelial space. This leads to unresolved inflammation
and a positive feedback mechanism which further aggravates the process. Endothelial
activation caused by inflammation induces the separation of endothelial cell junctions,
adhesion molecule presentation (e.g. VCAMs), and the secretion of chemokines (e.g.
MCP-1) to activate adhered monocytes. Activated monocytes extravasate through
endothelial cell gaps and become as macrophages under the influence of Granulocytemacrophage colony stimulating factor (GM-CSF). In addition to leukocytes, plasma
components such as LDL also extravasate into the sub-endothelial. Extravasated LDL is
oxidized by macrophage-derived reactive oxygen species, and oxLDL is phagocytosed by
the macrophages. Proinflammatory cytokines are released following oxLDL
phagocytosis, further activating macrophages and the endothelium. This aggravation
causes the release of vasoconstrictors, coagulation factors, and smooth muscle mitogens
that promote cell proliferation and migration into the sub-endothelial space, eventually
forming a neointima (Figure 2). While this process occurs naturally in the body, it can
also occur with treatment of atherosclerotic plaques after stent deployment.
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Figure 2 – Atherogenesis. The mechanistic etiology of atherogenesis from the cellular perspective [3].

Current Treatment for CHD
Catheter-based therapies are used as an alternative to bypass surgery for CHD
treatment due to its minimally invasive nature. The development of catheter-based
therapies began with balloon angioplasty, where plaque-occluded vessels were expanded.
The balloon angioplasty procedure deploys bare metal stents and addresses the poor
expansion reliability. Unfortunately, 3 years after bare metal stent implantation, 53% of
patients experienced in-stent restenosis (ISR), a phenomena in which smooth muscle cell
4

proliferation results in re-occlusion of the artery [4] . Restenosis was addressed by
coating bare metal stents with antiproliferative drugs that slowly elute over time. DES
elute antiproliferative agents to delay the restenosis response, but can undergo early-stent
thrombosis as soon as 30 days or late-stent thrombosis even years after implantation. The
mechanism for late-stent thrombosis is due to delayed healing by the drug on the stent
[5]. With further research, biomaterial design in stents will improve drug and
physiological interactions to help increase safety and efficacy (Figure 3).

Figure 3 - Stent Material Comparison. A stent is implanted by balloon angioplasty, which expands the
stent into its optimal diameter (left panel). The bare metal stent (top middle) undergoes restenosis while
the drug eluting stent (bottom middle) undergoes late-stage thrombosis. Both of these are problems that
stenting should prevent. The bioabsorbable polymer stent (right panel) reduces the risk of restenosis and
returns normal vessel function by dissolving into the blood stream [6].

As knowledge of stents and stent effects continue to grow, stent design will evolve to
address the various complications reported over time. This evolution will lead to more
sophisticated mechanisms used to manipulate the biologic response to stent implantation.
DES today manipulate known biological responses with an antiproliferative. A better
5

understanding of the underlying biology is needed to prevent proliferation of or recruit a
single cell type. To achieve this, a more sophisticated animal model will allow the
evaluation of the role of single proteins with knock-out mice or disease-like states with
specific animal models such as Apo -/- or non-obese diabetic (NOD) mice.

STENT USE AND ROLE IN CHD
Testing
Animal models used for stenting are restricted due to limited number of animals
with comparable human vasculature. Typical models include pigs and rabbits with the
porcine model widely accepted for the final stages of pre-clinical studies, due to the
geometric similarities to the human heart and coronary vasculature. The downside to
these animal models is that they develop very few to no atherosclerotic lesions, even with
a high-fat “western diet” [7]. As a solution, mice are widely used for early preclinical
research with the ability to easily manipulate genetics while being affordable. Current
genetically-modified mice for modeling CHD are ApoE -/- and LDL receptor -/- mice that
are susceptible to atherosclerosis and plaque development in turbulent flow areas (aortic
arch and abdominal aorta).

6

OBJECTIVE
The intent of this study was to better understand the neointimal hyperplasia
response to intravascular stents, which are the most commonly used strategy to re-open
occluded coronary arteries in human patients. In previous studies, a neointima was
formed in response to endothelial damage caused by stenting in mice [8]. In a similar
fashion, comparable stent injury was reproduced by catheterization of the abdominal
aorta.

Objective: Denude the abdominal aortic endothelium using an injury catheter to
induce neointima formation. The objective was to validate previous research and
to optimize the protocol for denuding the abdominal aorta.
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Chapter 2:

METHODS

Animal Housing and Care
Seven- to 9-week-old male C57Bl/6 mice from Taconic Farms were used for all
experiments according to approved protocols by the Cal Poly State University
Institutional Animal Care and Use Committee (IACUC). Mice were housed at the
University Vivarium in temperature-controlled rooms in microisolator cages. The
following enrichment items were provided: a “mouse house”, nesting material, and a
plastic tube. Mice were monitored daily, given water and rodent chow ad libitum, and
maintained on a 12 hour light/dark cycle (LD 12:12). Cages were changed weekly using
aseptic technique.

Aortic Endothelial Denudation Protocol
An induction chamber with 5% isoflurane in oxygen flowing at ~3 l·min-1 was
used to anesthetize the mouse. The mouse was then weighed and transferred to a
preparatory bench where anesthesia was reduced to ~1-3% isoflurane in oxygen flowing
at 0.5-1.0 l·min-1. Hindlimb hair was removed with clippers and depilatory cream before
placing the animal supine on a heated surgical stage under a dissection scope. Body
temperature was kept at ~35° C by a heat pad controlled with a rectal thermistor probe.
A small incision was made on the middle, medial aspect of the left hindlimb,
directly over the femoral neurovascular bundle, and extended proximally to the
abdominal wall. The area was continually irrigated with phosphate buffered saline (PBS)
throughout the procedure to prevent desiccation. Connective tissue was blunt dissected
while a heat cautery was used to remove the epigastric fat pad and a majority of the
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epigastric neurovascular bundle. The superficial femoral artery was separated from its
vein and nerve pair, and arteriotomy performed just upstream to the profunda femoris.
The catheter was inserted into the femoral artery just proximal to the profunda femoris
branch (Figure 4) and advanced into the abdominal aorta to denude the endothelium.
Following aortic endothelial denudation, the catheter was partially retracted and 100
I.U./mL of heparinized saline was injected through the catheter followed by 50 µL of 40
mg/mL Evans blue dye.
After the dye circulated, the animal was perfuse fixed with 4% paraformaldehyde
(PFA). For the perfusion fixation procedure, a thoracotomy was performed to expose the
heart. The left ventricle was then catheterized and connected to a syringe pump for the
infusion of PBS following by PFA. An incision was made in the right atrium for solution
drainage; for a detailed description of the surgical procedure refer to the Appendix.

kidney

aorta

catheter direction

arteriotomy site

femoral artery

Figure 4 – Catheterization Procedure Diagram. Illustration of the aortic endothelial denudation
protocol procedure.
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Imaging Analysis
Infinity imaging software (Lumenera) was used to capture images and ImageJ
was used to add scale bars. ImageJ was calibrated using a stage micrometer scale at the
appropriate magnification.
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Chapter 3:

RESULTS

The results demonstrate a progression of adjustments made to the protocol while using
the injury catheter. Figure 5 illustrates a poor Evans Blue and PBS perfusion in the
abdominal aorta, where the dye was injected into the left ventricle of the heart after
denudation. Modification to the Evans Blue injection is reflected in Figures 6-8 where the
dye was introduced through the injury catheter following endothelial denudation.

adipose

aorta

Figure 5 – Poor Evans Blue Stain and Perfusion Fixation of Abdominal Aorta. Evans Blue stain is
too dark due to poor perfusion fixation.
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renal artery

aorta

severe denudation

Figure 6 – Ineffective Evans Blue Stain and Denudation of Abdominal Aorta. Blue staining is
inconsistent throughout aorta. More damage near iliac bifurcation (darker Evans Blue) due to difficulties
advancing injury catheter.
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renal artery

ineffective denudation

aorta

Figure 7 – Evans Blue Stain with Ineffective Denudation of Abdominal Aorta. Denudation of aorta
can be seen distal the left renal artery and needed to be more proximal.
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(1)

(2)
(3)

(4)

effective denudation
aorta

(5)
(6)

Figure 8 – Successful Evans Blue Stain and Denudation of Abdominal Aorta. The blue staining of the
vessel indicates where endothelial denudation has occurred. (1) - Right renal artery (clear) (2) - Left
renal artery (clear) (3) – Upper aabdominal aorta (clear) (4) – Lower abdominal
bdominal aorta (blue) (5) - Right
iliac (clear) (6) - Left iliac (blue)
(blue).

Figure 8 shows an image of a specimen’s dissected aorta stained with Evans Blue
dye, indicating successful endothelial denudation. The Evans Blue dye was used to
confirm denudation and works by staining albumin which adheres to the basement
membrane of the vessel in areas where the endothelium is damaged
damaged.
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Chapter 4:

DISCUSSION

CHD decreases heart function and blood flow through the coronary arteries due to
atherosclerotic plaque buildup, which is commonly treated by stenting. New types of
stent designs yield new challenges to solve, like the advent of DES and problems with
late-stent thrombosis. To address this, we need additional research models to assist
understanding the responses of the vascular wall to stent implantation. This mouse model
can serve as the foundation to build upon and to help with the design of newer research
models.

Success of the Protocol Development
The developed protocol was demonstrated successfully with the refinement of the
surgical procedure to produce endothelial denudation (Figure 8). The injury catheter was
advanced through the left iliac and into the abdominal aorta to the left renal artery. Due to
the damage, the basement membrane was exposed, which allows the Evans Blue to stain
the tissue by binding to the localized albumin. In the clear areas, the basement membrane
is not exposed, which does not allow albumin to adhere, allowing the vessel to remain
unstained.

Challenges and Improvements
Initial experiments revealed difficulty with inserting the injury catheter into the
femoral artery. This was due to the device and vessel diameter being similar in size. To
overcome this challenge, a smaller diameter catheter was used while learning how to
properly perform the arteriotomy and gradually increased to the required catheter size to
denude the vessel. The purpose of the larger catheter size was twofold. The larger size
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allowed for easier endothelial denudation without tearing, as well as a vehicle for
deployment and future testing of experimental polymeric stents.
Later experiments were difficult due to tactile unfamiliarity with vessel anatomy
and blind catheterization with the injury catheter. If the vessel tore at the arteriotomy site
during an experiment, the mouse was used to practice perfusion fixation. If the vessel
perforated in the abdominal region, a practice dissection of the abdominal aorta was
performed. Utilization of the mouse in failed attempted procedures proved helpful to gain
more experience in mastering other areas of the protocol. After many experiments,
confidence with tactile feedback grew along with technical skill. Another challenge
included poor Evans Blue dye perfusion and blood coagulation during perfusion fixation.
This was addressed with the addition of polyethylene (PE-100) tubing joining the injury
catheter to a Luer-Lok mechanism (Figure 9 in Appendix). It is important to note that
there should be sufficient slack available in the tubing so that the Luer-Lok will not catch
onto the surgical stage. Also, more slack allows for more tactile feedback from the
catheter due to the weight distribution over a longer length of the tubing preventing it
from “pulling” the catheter as much.
Learning the Evans Blue staining protocol revealed inconsistencies with the acute
denudation experiment completed before. A heterogeneous denudation pattern was
observed throughout the vessel where the catheter traveled. Improvements made in the
protocol involved the twisting movement of the catheter during retraction. This increased
the amount of damage and homogeneity observed by the Evans Blue stain, particularly
inferior to the left renal artery.
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Future Work
This optimized protocol will be used in future experiments which will include a
chronic 28-day study to determine if the formation of a neointima occurs in the denuded
regions of the abdominal aorta. We are interested in assessing neointimal formation in
response to injury and/or bioresorbable stent implantation. Neointima formation is
clinically caused by the endothelial damage left by stent implantation. This damage
causes smooth muscle cell proliferation into the intima of the artery. The intimal
thickening causes the artery to undergo restenosis where the vessel wall grows around the
stent struts, occluding a majority of the blood flow through the vessel. Therefore
prevention of this neointima is key to solving the issues plaguing stent and angioplasty
usage. In the future, this model can be used to characterize gene expression and assess
specific molecular pathways that contribute to restenosis and thrombosis.
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APPENDIX
Aortic Endothelial Denudation Protocol
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Evans Blue & Perfusion Fixation Protocol
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Photographs of Procedure

Figure 9 – Assembled Injury Catheter. Preparation of injury catheter with
ith heparinized saline 100
I.U./mL.

Figure 10 – Femoral Artery Catheterization. Successful
uccessful catheterization of the injury catheter before
bef
advancement into the abdominal aorta.
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Figure 11 – Evans Blue Injection. 50 µ L of 40 mg/mL of Evans Blue delivered directly into the blood
with 100 I.U./mL heparinized saline through the injury catheter.
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Figure 12 – After a Perfusion Fixation Protocol. (1) - Clear liver indicates successful perfusion of 4%
PFA/PBS and removal of blood (2) - Blue stained intestine indicates
tes perfusion of Evans blue dye (3) Left hind paw not stained blue ddue to ligation distal to insertion site (no blood flow) (4) - Right hind paw
stained indicates circulation of dye throughout extremities

27

